December 21, 2022Press Release
Artificial Intelligence Tool Predicts Which Patients with Dystonia Respond to Botox Treatment with 96 Percent Accuracy
Program Director, External Communications - Research, Mass General Brigham
617-573-4385 | firstname.lastname@example.org
DystoniaBoTXNet platform can fill treatment knowledge gaps and address challenges in over- and under-prescribing of first-line treatment for dystonias.
Boston, Mass. – Dystonias are potentially disabling neurological conditions that can greatly affect quality of life. Effective treatments are sparse, with botulinum toxin (Botox) injections into the affected muscles considered the first-line therapy. However, the injections do not work for every patient with dystonia, and there has been no established way for clinicians to determine who would benefit and who would not prior to treatment initiation.
In a new study published November 28 in Annals of Neurology, an artificial intelligence platform called DystoniaBoTXNet used brain MRIs to automatically identify which patients would respond to botulinum toxin treatment with 96.3 percent accuracy. Such a platform can inform clinicians’ treatment decisions, according to senior study author Kristina Simonyan, MD, PhD, Dr med, director of Laryngology Research at Mass Eye and Ear, a member of Mass General Brigham, and professor of Otolaryngology–Head and Neck Surgery at Harvard Medical School.
“Typically, a patient with dystonia would undergo a series of dose- and location-finding injections to determine whether botulinum toxin relieves their symptoms. Injections are painful and costly,” said Dr. Simonyan. “Yet, some may find no benefits from this treatment despite multiple injection attempts, while some might benefit from injections but give up after only one dose or forgo the treatment altogether. With this artificial intelligence algorithm, we can empower clinicians and patients in their therapeutic decision-making by providing them with an objective tool to replace the trial-and-error approach to botulinum toxin efficacy.”
Pervasive Treatment Challenges for Patients with Dystonia
People with dystonias experience involuntary contractions or tensing of muscles which can lead to uncontrolled movements that significantly impact physical and emotional quality of life. Isolated focal dystonias affect one part of the body, with common examples including: laryngeal dystonia affecting the vocal cords when speaking, blepharospasm causing involuntary eyelid twitching, cervical dystonia causing the neck muscles to contract and the head to twist painfully and writer’s cramp dystonia affecting the fingers during writing. About 35 of every 100,000 people have isolated or primary dystonia – a prevalence that is likely underestimated due to challenges diagnosing the disorder.
Botulinum toxin injections are considered the first-line treatment for focal dystonias. The injection paralyzes the affected muscle, aiming to prevent the involuntary contractions. The effects are usually temporary, and an injection often needs to be repeated every three-four months for life.
Only about 60 percent of patients with dystonias undergo these injections, and not every patient responds to treatment. This can be due to underlying biological reasons, complexity of symptoms or the experience and expertise of the injecting physician. This may lead to an overtreatment of patients who would not respond to botulinum toxin in the first place, and an undertreatment of patients who may respond but never seek out the treatment or might stop the treatment early.
This high variability led Dr. Simonyan and her team to turn to artificial intelligence for finding a solution to objectively assess the benefits of botulinum toxin injections prior to treatment initiation.
Predicting Treatment Effectiveness with MRIs
In the new study published in Annals of Neurology, the research team trained a deep-learning algorithm to analyze the brain MRIs of 284 patients with four types of dystonia who responded and did not respond to botulinum toxin injections. Efficacy of the injections was determined by medical records and physician and patient feedback.
DystoniaBoTXNet revealed there were eight regions of the brain as a neural biomarker of effectiveness of injections. Using this newly discovered biomarker, DystoniaBoTXNet achieved an overall accuracy of 96.3 percent in predicting botulinum toxin efficacy in focal dystonia, with 100 percent sensitivity and 86.1 percent specificity. The platform achieved these results in 19.2 seconds per case.
“Our study shows that DystoniaBoTXNet can be a very robust and easy-to-use AI platform for physicians to use for refined clinical decisions. An AI-generated individual predictive outcome of botulinum toxin injections prior to treatment administration may help more precise patient selection, fine-tuning of the treatment regimen, or further referrals, thus increasing utilization of botulinum toxin for patients with dystonia," Dr. Simonyan offered as an example. “On the other hand, the platform may predict that the patient has very low probability of benefiting from injections, which would be informative for the physician to consider other therapeutic options instead of botulinum toxin overtreatment.”
Artificial Intelligence Tackles Problems with Dystonia Diagnosis and Treatment
The DystoniaBoTXNet tool is the second artificial intelligence platform invented by Dr. Simonyan and her team to aid clinical decision-making. This study builds on previous research led by this team that reported on the success of a separate platform called DystoniaNet capable of diagnosing dystonia from patient MRIs with 98.8 percent accuracy in 0.36 seconds. Dystonias are notoriously mis- and under-diagnosed, with some studies showing it can take patients up to 10 years to receive a proper diagnosis.
Interestingly, five of the eight regions identified as a neural biomarker of botulinum toxin efficacy by DystoniaBoTXNet in the new paper were previously found to constitute the diagnostic biomarker of DystoniaNet. For years, clinicians have had no objective biomarker for identifying these conditions, therefore the overlapping regions may provide added evidence to their roles in dystonia that scientists can better explore.
With further study of both platforms, the hope is that one day a patient can enter a clinician’s office after experiencing symptoms and undergo an MRI and receive a diagnosis through DystoniaNet; then, DystoniaBoTXNet can help determine whether botulinum toxin treatment would work for them.
To achieve this goal, the researchers are embarking on multiple clinical trials within Mass General Brigham to determine the usefulness of these tools in the clinic. Another future direction of the work is to study whether additional treatments, like deep brain stimulation, might be predicted by an AI-based tool.
In addition to Dr. Simonyan, co-authors of the study in her Mass Eye and Ear lab were Dongren Yao, PhD, and Lena O’Flynn, BA. This study was funded by the National Institutes of Health (NIH grants R01DC012545, R01DC011805, R01NS088160, R01NS124228 to KS), the Mass General Brigham Innovation Discovery Grant, the Amazon Web Services Machine Learning Research Award, and a charitable gift by Mr. and Mrs. Richardson. The authors declare a U.S. patent, with Dr. Simonyan and Dr. Yao listed as the inventor.
About Mass Eye and Ear
Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass Eye and Ear specializes in ophthalmology (eye care) and otolaryngology–head and neck surgery (ear, nose and throat care). Mass Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 2022–2023 “Best Hospitals Survey,” U.S. News & World Report ranked Mass Eye and Ear #4 in the nation for eye care and #4 for ear, nose and throat care. For more information about life-changing care and research at Mass Eye and Ear, visit our blog, Focus, and follow us on Instagram, Twitter and Facebook.